Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12494569 | 0.98 | GAA (0.51) | GAAALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL15139546 | 0.92 | GAA (0.47) | GAAALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL23219976 | 0.89 | ALDH1A1 (0.47) | GAAALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL10282470 | 0.87 | TSHR (0.47) | GAAALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL13141433 | 0.87 | TSHR (0.47) | GAAALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL13154266 | 0.87 | TSHR (0.47) | GAAALDH1A1NPC1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL15971126 | 0.85 | TSHR (0.45) | GAAALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL15451695 | 0.83 | GAA (0.50) | GAAALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL20993453 | 0.82 | EPHX1 (0.45) | GAAEPHX1TSHRMAPTCHRNB2 | |
| SCHEMBL6495220 | 0.82 | EPHX1 (0.45) | GAAALDH1A1NPC1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | claimed |
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | claimed |
| CN-116102565-A | Isolamine-containing spirochromone compound and preparation method and application thereof | 贵州大学 | 2023-05-12 | — | — | CN | claimed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | claimed |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | claimed |
| US-20180244672-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2018-08-30 | — | — | US | claimed |
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | claimed |
| EP-1817036-B1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2012-07-04 | — | — | EP | claimed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | claimed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | claimed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | claimed |
| CN-119751359-A | Benzo five-membered heterocyclic compound containing hydrazone structure and application thereof | 贵州大学 | 2025-04-04 | — | — | CN | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118047763-A | Saturated nitrogen heterocyclic compound containing pyrimidine structure, and preparation method and application thereof | 贵州大学 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024039883-A2 | COMPOSITIONS AND METHODS TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20040102627-A1 | 3-Amino-piperadine derivatives and methods of manufacture | PFIZER INC. | 2004-05-27 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | GAA 1654/4885ALDH1A1 901/4885NPC1 3361/4885 |
| US-20040102627-A1 | 3-Amino-piperadine derivatives and methods of manufacture | PRMT5, SRM, CYP1B1 | GAA 4211/4885ALDH1A1 12/4885NPC1 2112/4885 |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | GAA 1654/4885ALDH1A1 901/4885NPC1 3361/4885 |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | GAA 1654/4885ALDH1A1 901/4885NPC1 3361/4885 |
| US-20180244672-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | GAA 1654/4885ALDH1A1 901/4885NPC1 3361/4885 |
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | GAA 2703/4885ALDH1A1 1636/4885NPC1 949/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | GAA 4525/4885ALDH1A1 1572/4885NPC1 1363/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | GAA 1713/4885ALDH1A1 1851/4885NPC1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.